AI summary by TwinMind
Extra: Why Is 23andMe Going Under? (Update) | Freakonomics Radio
Freakonomics Radio Network
1h 2m 4s
Introduction and Context
- Steven Dubner introduces bonus episode about 23andMe's dramatic decline
- Company valued at $6 billion in 2021 after going public via SPAC backed by Richard Branson
- Current valuation: effectively zero according to Wall Street Journal reporter Ralph Winkler
- Episode replays 2019 interview with CEO Anne Wojcicki with updated analysis
Golden State Killer Case and DNA Privacy Concerns
- 2018 arrest of Golden State killer using DNA genealogy through GEDmatch
- Detectives uploaded suspect DNA to open-source genealogy site
- 24 relatives found in database, cross-referenced with census/cemetery records
- Raised concerns about privacy and law enforcement use of consumer DNA data
- Wojcicki emphasized 23andMe's early focus on preventing crime/FBI misuse through consent forms
Anne Wojcicki Background and Company Origins
- Youngest of three daughters: Stanley Wojcicki (Stanford physics professor), Esther Wojcicki (educator/journalist)
- Sister Susan was YouTube CEO, sister Janet is anthropologist/epidemiologist
- Google connection: Susan rented garage to Larry Page/Sergey Brin; Anne married Sergey Brin (divorced 2015)
- Yale biology degree, varsity ice hockey, Wall Street healthcare analyst for 10 years
- Became cynical about healthcare system profiting from illness, not wellness
- Larry Page challenged her: "part of solution or part of problem"
Company Formation and Business Model
- Co-founded 23andMe in 2006 with Linda Avey and Paul Cusenza
- Direct-to-consumer personal genomics company
- $100 ancestry test, additional $100 for health reports
- 10 million total customers, 5 million bought health reports
- World's largest genetic database for medical research
FDA Regulatory Challenges
- November 2013: FDA warning letter demanding halt to health information
- Company didn't believe they were medical device, FDA disagreed
- Had to stop interpreting health data, continue raw data/ancestry only
- Wojcicki: "grateful to FDA" for safety oversight despite initial upset
- 2017: FDA approved genetic risk reports for 10 conditions including breast/ovarian cancer, Alzheimer's, Parkinson's
Health Risk Reports and Polygenic Scoring
- 2019: Launched type 2 diabetes risk report using polygenic risk scores
- Used data from 2.5 million consenting customers
- Method analyzes thousands/millions of small genetic effects vs single genes
- Criticized for being "tuned for skinny white people" due to European-heavy database
- 20% of customers non-European, but largest such database globally
Diversity and Representation Issues
- Database overwhelmingly European descent, problematic for conditions like diabetes affecting African Americans disproportionately
- Historical medical exploitation of African Americans creates participation reluctance
- Global genetic diversity project recruiting from Tanzania, Cameroon, Chad with free testing
- Goal: develop reports representative of all populations
Behavioral Change and Health Outcomes
- Limited evidence genetic risk information leads to sustained behavior change
- Harvard study: 40% reported diet changes at 6 months, but self-reported data unreliable
- 2016 British Medical Journal: no evidence genetic testing changes behaviors
- Wojcicki optimistic about human potential for change with right tools
- Partnerships with AI coaching (Lark) to help behavior modification
Research Partnerships and Data Monetization
- 2018: GSK $300 million investment for drug discovery rights
- Additional partnerships: Pfizer, Genentech, Procter & Gamble
- Over 150 publications, hundreds of studies across diseases
- Massive disease cohorts: 19,000 Parkinson's, 1 million high Alzheimer's risk, 800,000 heart disease
- 13-14 compounds in research/development pipeline
- Customers want results, not $50 checks for data use
Privacy and Security Measures
- Banking-level security infrastructure from early days
- Never been substantially hacked (as of 2019 interview)
- Explicit consent required for individual-level data sharing
- Pioneered granular sharing options vs restrictive HIPAA model
- Customer choice emphasized: opt-in/opt-out flexibility
Family Revelations and Genetic Discoveries
- Personal example: Sergey Brin's Parkinson's mutation discovery
- Wojcicki family discovered unknown cousin through platform
- Redefining family connections, especially for Holocaust survivors
- New literary genre: DNA discovery memoirs revealing family secrets
- End of anonymous adoption/sperm donation era
- Powerful psychological impact of genetic vs mirror-based identity
Company Decline Analysis (Ralph Winkler Interview)
- SPAC projections failed: promised 1 million subscription customers, fell far short
- One-time product problem: customers only test once, no recurring revenue
- Subscription model ($70/year) failed to gain traction
- Drug discovery takes decades, clinical trials uncertain
- 2023 hack damaged consumer trust (ashkenazi Jewish data targeted)
- Current enterprise value: zero (stock price equals cash in bank)
Current State and Future Prospects
- Wojcicki controls 49.99% voting shares, considering taking company private
- Two cancer drugs in clinical trials
- Winkler believes company sincere about healthcare mission despite business failure
- Prediction: similar operations under private ownership within 2-3 years
- Fundamental challenge: monetizing wellness vs illness remains unsolved
